BI0110 ADC

BI0110 ADC is a discovery-stage antibody-drug conjugate (ADC) developed by Protheragen for the treatment of solid tumors. The agent specifically targets Claudin 6 (CLDN6), a tight junction protein that is frequently overexpressed in various cancers—including ovarian, lung, and gastric cancers—while remaining largely absent in healthy adult tissues. By utilizing a monoclonal antibody specific to CLDN6 conjugated to a cytotoxic payload, BI0110 ADC is designed to selectively deliver potent anti-tumor agents to malignant cells, thereby enhancing the therapeutic window and reducing systemic side effects compared to traditional chemotherapy.